Clinical Trial Update: Safety and Efficacy Study of Human T Lymphoid Progenitor (HTLP) Injection After Partially HLA Compatible Allogeneic Hematopoietic Stem Cell Transplantation in SCID Patients [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on HTLP injection after partially HLA-compatible HSCT in SCID patients, encompassing Phase 1 and Phase 2, with unknown current status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Combined Immunodeficiency

Drugs mentioned

• HTLP injection

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Pediatric Patients, Any Type of Severe Combined Immunodeficiency (SCID) | Phase 1, Phase 2 | Status: UNKNOWN